Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Revenue: $944 million in 2025, a 34% increase year-over-year. Commercial Products Revenue: $436 million, representing 46% of total revenue. R&D Collaborations Revenue: $508 million, representing 54% of total revenue. TRYNGOLZA Sales: $108 million in 2025, with $50 million in Q4, a 56% increase over Q3. DAWNZERA Sales: $8 million in 2025 from initial launch months. Royalty Revenues: Increased 11% to $285 million in 2025. Operating Expenses: Increased modestly year-over-year, driven by launch investments. Projected 2026 Revenue: $800 million to $825 million, a 20% increase over adjusted 2025 figures. Projected 2026 Operating Loss: Between $500 million and $550 million. Cash and Investments: Projected to end 2026 with approximately $1.6 billion. Warning! GuruFocus has detected 5 Warning Sign with IONS. Is IONS fairly valued? Test your thesis with our free DCF calculator. Release Date: February 25, 2026 For the complete
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by Needham & Company LLC.MarketBeat
- Ionis Pharmaceuticals (IONS) had its "outperform" rating reaffirmed by Royal Bank Of Canada.MarketBeat
- Ionis Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 2/25/26 - Miss
IONS
Sec Filings
- 2/25/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- 2/13/26 - Form 4/A
- IONS's page on the SEC website